Want to see ELVN full AI Analyst Report?
Top Page
Enliven Therapeutics
(NASDAQ:ELVN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$42.00
▼(-30.58% Downside)
Action:Reiterated
Date:10/14/26
The score is primarily constrained by weak financial performance—no revenue, sizable ongoing losses, and continued cash burn—despite a strong, low-debt balance sheet. Technical indicators also point to a pronounced downtrend (below major moving averages with very low RSI/Stoch and negative MACD). Valuation is difficult to support using P/E due to negative earnings, while the recent board appointment is a modest positive but not enough to offset the fundamental and technical headwinds.
Positive Factors
Low financial leverage
Minimal debt relative to the equity base reduces balance-sheet financial risk and preserves flexibility while Enliven funds clinical development. Substantial asset growth also indicates stronger capitalization, providing a more durable foundation for advancing programs despite the company’s pre-commercial status.
Negative Factors
Pre-commercial business model
The absence of revenue means Enliven has not yet demonstrated commercial demand or an operating revenue base to fund its activities. Its near- and medium-term financial profile therefore remains dependent on clinical progress and eventual product approval rather than established sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Minimal debt relative to the equity base reduces balance-sheet financial risk and preserves flexibility while Enliven funds clinical development. Substantial asset growth also indicates stronger capitalization, providing a more durable foundation for advancing programs despite the company’s pre-commercial status.
Read all positive factors
Enliven Therapeutics (ELVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.20B
Dividend YieldN/A
Average Volume (3M)1.64M
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue GrowthN/A
EPS Growth16.63%
CountryUS
Employees67
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.64
Shares Outstanding73,270,760
10 Day Avg. Volume1,755,658
30 Day Avg. Volume1,644,172
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-41.08K
Enterprise Value/Ebitda-23.29
Forecast
1Y Price Target
$74.33Price Target Upside22.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.86
Revenue Forecast (FY)N/A
Enliven Therapeutics Business Overview & Revenue Model
Company Description
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small ...
Enliven Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -60.00K | -263.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -105.80M | -103.43M | -88.47M | -71.29M | -37.45M | -24.63M |
| Net Income | -105.93M | -103.69M | -89.02M | -71.58M | -37.66M | -24.74M |
Balance Sheet | ||||||
| Total Assets | 910.22M | 476.17M | 325.76M | 271.87M | 83.30M | 113.33M |
| Cash, Cash Equivalents and Short-Term Investments | 895.15M | 462.62M | 313.44M | 253.15M | 75.54M | 110.02M |
| Total Debt | 1.51M | 399.00K | 0.00 | 335.00K | 323.00K | 159.00K |
| Total Liabilities | 15.07M | 16.68M | 15.91M | 25.96M | 160.12M | 6.47M |
| Stockholders Equity | 895.15M | 459.60M | 309.85M | 245.91M | -76.83M | 106.86M |
Cash Flow | ||||||
| Free Cash Flow | -67.04M | -70.46M | -73.24M | -61.42M | -32.69M | -19.32M |
| Operating Cash Flow | -66.94M | -70.30M | -73.19M | -61.27M | -32.08M | -19.13M |
| Investing Cash Flow | -390.72M | -173.84M | -36.00M | -148.41M | -612.00K | -191.00K |
| Financing Cash Flow | 473.73M | 218.87M | 133.16M | 234.29M | -1.80M | -1.02M |
Enliven Therapeutics Technical Analysis
Positive
60.50
Price Trends
49.59
Negative
50.24
Negative
42.45
Positive
Market Momentum
-1.98
Negative
49.46
Neutral
81.13
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELVN, the sentiment is Positive. The current price of 60.5 is above the 20-day moving average (MA) of 41.83, above the 50-day MA of 49.59, and above the 200-day MA of 42.45, indicating a neutral trend. The MACD of -1.98 indicates Negative momentum. The RSI at 49.46 is Neutral, neither overbought nor oversold. The STOCH value of 81.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELVN.
Enliven Therapeutics Risk Analysis
Enliven Therapeutics disclosed 89 risk factors in its most recent earnings report. Enliven Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enliven Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $3.23B | -17.45 | -16.47% | ― | 3244.67% | 49.14% | |
56 Neutral | $3.86B | -26.93 | -25.74% | ― | 121.47% | 36.95% | |
55 Neutral | $4.13B | -12.00 | -42.27% | ― | 23.86% | 19.60% | |
54 Neutral | $4.98B | -10.81 | -24.39% | ― | -64.80% | 12.20% | |
52 Neutral | $4.18B | -43.12 | -8.70% | ― | 59.59% | 71.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $3.20B | -26.64 | -18.55% | ― | ― | 16.63% |
* Healthcare Sector Average
ELVN
Enliven Therapeutics
43.69
21.04
92.89%
CRSP
Crispr Therapeutics AG
51.47
-11.09
-17.73%
IDYA
IDEAYA Biosciences
33.50
1.32
4.10%
LEGN
Legend Biotech
21.56
-10.57
-32.90%
RLAY
Relay Therapeutics
18.84
11.53
157.73%
TNGX
Tango Therapeutics
22.89
15.06
192.34%
Enliven Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Enliven Therapeutics Adds Director to Support Growth
Positive
Oct 14, 2026
On October 14, 2026, Enliven Therapeutics expanded its board from seven to eight members and appointed biopharmaceutical executive Kristine Ball as a Class II director and Audit Committee member, with her term running until the 2028 annual meeting...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.